Valerio Brisigotti

Valerio Brisigotti

Auto-generated profile, based on publicly available information

Valerio Brisigotti

Dermatological Unit, Department of Clinical and Molecular Sciences Polytechnic Marche University Ancona Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
Roberto CampagnaRoberto Campagna
Roberto Campagna
TBTiziana Bacchetti
Tiziana Bacchetti
Eleonora SalvoliniEleonora Salvolini
Eleonora Salvolini
Valentina PozziValentina Pozzi
Valentina Pozzi
EMElisa Molinelli
Elisa Molinelli
Monica EmanuelliMonica Emanuelli
Monica Emanuelli
Melanoma represents the most aggressive skin cancer, being responsible for the majority of deaths related with these neoplasms. Despite chemotherapy represents a frontline approach for management of the advanced stages of the disease, it displayed poor response rates and short-term efficacy due to melanoma cell resistance. Therefore, the discovery of molecules that can be used for effective targeted therapy of melanoma is crucial. In this study, we evaluated the impact of paraoxonase-2 (PON2) silencing on proliferation, viability, and resistance to treatment of the A375 melanoma cell line with chemotherapeutic drugs dacarbazine (DTIC) and cisplatin (CDDP). Due to the enzymes ability to counteract oxidative stress, we also evaluated the effect of enzyme knockdown on reactive oxygen species (ROS) production in cells treated with CDDP. The data reported clearly demonstrated that PON2 knockdown led to a significant reduction of cell proliferation and viability, as well as to an enhancement of A375 sensitivity to CDDP treatment. Moreover, enzyme downregulation was associated with an increase of ROS production in CDDP-treated cells. Although further analyses will be necessary to understand how PON2 could influence melanoma cell metabolism and phenotype, our results seem to suggest that the enzyme may serve as an interesting molecular target for effective melanoma treatment.

30 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Roberto CampagnaRoberto Campagna
Roberto Campagna
Valentina PozziValentina Pozzi
Valentina Pozzi
Davide SartiniDavide Sartini
Davide Sartini
Eleonora SalvoliniEleonora Salvolini
Eleonora Salvolini
VBValerio Brisigotti
Valerio Brisigotti
Monica EmanuelliMonica Emanuelli
Monica Emanuelli
Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with the two pre-neoplastic conditions Bowen disease (BD) and actinic keratosis (AK). Both malignant melanoma and NMSC are showing an increasing incidence rate worldwide, thus representing an important challenge for health care systems, also because, with some exceptions, SC are generally characterized by an aggressive behavior and are often diagnosed late. Thus, identifying new biomarkers suitable for diagnosis, as well as for prognosis and targeted therapy is mandatory. Nicotinamide N-methyltransferase (NNMT) is an enzyme that is emerging as a crucial player in the progression of several malignancies, while its substrate, nicotinamide, is known to exert chemopreventive effects. Since there is increasing evidence regarding the involvement of this enzyme in the malignant behavior of SC, the current review aims to summarize the state of the art as concerns NNMT role in SC and to support future studies focused on exploring the diagnostic and prognostic potential of NNMT in skin malignancies and its suitability for targeted therapy.

24 June 2020 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
EMElisa Molinelli
Elisa Molinelli
VBV. Brisigotti
V. Brisigotti
OSO. Simonetti
O. Simonetti
ACAnna Campanati
Anna Campanati
CSC. Sapigni
C. Sapigni
AOA. Offidani
A. Offidani

18 March 2022 in Dermatologic Therapy
Verified
Journal Article
Open access
EMElisa Molinelli
Elisa Molinelli
VBValerio Brisigotti
Valerio Brisigotti
OSOriana Simonetti
Oriana Simonetti
CSClaudia Sapigni
Claudia Sapigni
GDGiovanni Marco D'AGostino
Giovanni Marco D'AGostino
AOAnnamaria Offidani
Annamaria Offidani
Topical and systemic antibiotic therapy remains the first‐line treatment for mild‐to‐moderate hidradenitis suppurativa (HS). However, literature data on antibiotic resistance in HS are growing. A total of 134 patients with mild‐to‐moderate HS were retrospectively evaluated. Seventy‐three patients (group A) received topical clindamycin 1% and 61 patients (group B) received topical resorcinol 15%. We evaluated the efficacy and tolerability of topical 15% resorcinol versus topical 1% clindamycin in mild‐to‐moderate HS, comparing the clinical response at 12 weeks of treatment. Patients treated with resorcinol 15% showed a significant improvement in Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System, and Pain Visual Analogue Scale score from baseline compared to patients treated with clindamycin 1%. Topical resorcinol 15% could be a valid alternative to clindamycin in the management of acute and long‐standing HS, limiting antibiotic use and antimicrobial resistance.

24 July 2021 in Human Cell
Verified
Journal Article
Closed access
PDF file
Davide SartiniDavide Sartini
Davide Sartini
Roberto CampagnaRoberto Campagna
Roberto Campagna
Guendalina LucariniGuendalina Lucarini
Guendalina Lucarini
VPVeronica Pompei
Veronica Pompei
Eleonora SalvoliniEleonora Salvolini
Eleonora Salvolini
Monica EmanuelliMonica Emanuelli
Monica Emanuelli

19 July 2020 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
RCR.D. Caposiena Caro
R.D. Caposiena Caro
EMElisa Molinelli
Elisa Molinelli
VBV. Brisigotti
V. Brisigotti
AOA. Offidani
A. Offidani
LBLuca Bianchi
Luca Bianchi